Related Experiment Video
Updated: Mar 6, 2026

09:47
Author Spotlight: Advancing Alzheimer's Research – Exploring Early Detection and Multi-Omics Approaches
Published on: December 15, 2023
2.0K
Spatiotemporal profiling of functional network overlapping modules in Alzheimer's disease
Yue Gu1, Ying Lin1, Liangfang Li1
1Department of Psychology, Sun Yat-sen University, Guangzhou, China.
Network Neuroscience (Cambridge, Mass.)
|March 5, 2026
Summary
Alzheimer's disease (AD) shows altered brain network organization with more overlapping modules and decreased modularity. These changes in overlapping nodes are linked to amyloid buildup and cognitive decline in AD patients.
Area of Science:
- Neuroscience
- Medical Imaging
- Network Science
Background:
- Alzheimer's disease (AD) involves progressive neural network degradation.
- Overlapping module structures in brain networks offer more accurate functional representations than nonoverlapping ones.
- Understanding dynamic functional changes in overlapping brain modules is crucial for insights into AD.
- The spatiotemporal dynamics of overlapping modular brain organization in AD are not fully understood.
Purpose of the Study:
- To explore the overlapping modular organization and dynamic multilayer modules in Alzheimer's disease (AD) using resting-state fMRI.
- To compare brain network organization between AD patients and healthy controls (HC).
- To investigate the relationship between overlapping nodal characteristics, amyloid deposition, and cognitive performance in AD.
Main Methods:
- Resting-state functional magnetic resonance imaging (fMRI) was used.
- Data were collected from 64 AD patients and 61 healthy controls (HC) from the Alzheimer's Disease Neuroimaging Initiative.
- Analysis focused on overlapping modular organization, dynamic multilayer modules, nodal overlapping probability, and modularity.
- Lasso regression was employed to correlate network characteristics with cognitive performance.
Main Results:
- Alzheimer's disease (AD) patients exhibited increased overlapping modules and decreased modularity compared to healthy controls (HC).
- Altered nodal overlapping probability was observed, particularly in the superior frontal cortex and hippocampus.
- Higher nodal overlapping probability correlated with increased functional flexibility and larger amyloid deposits.
- Overlapping nodal characteristics showed strong correlations with cognitive performance.
Conclusions:
- Overlapping nodes are critical components in Alzheimer's disease (AD) pathology.
- These nodes demonstrate high amyloid deposition, significant functional flexibility, and strong associations with cognitive behavior.
- Findings enhance understanding of AD pathology and may aid in developing diagnostic and therapeutic biomarkers.
Keywords:
Alzheimer’s diseaseMultilayer dynamic networksOverlapping modular organizationOverlapping nodeTemporal variabilityMore Related Videos
Related Concept Videos
Alzheimer's Disease: Overview
1.9K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.9K
Alzheimer's Disease: Treatment
1.1K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.1K

